ArticleBMC cardiovascular disorders2026
A pragmatic nomogram using routinely collected clinical variables to screen prevalent HFpEF: development and temporal validation.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesTo develop and temporally validate a pragmatic nomogram based on routinely available clinical and laboratory variables to estimate the individualized probability of prevalent heart failure with preserved ejection fraction (HFpEF) at the index assessment, and to support screening or triage, and prioritization for confirmatory echocardiography in settings where comprehensive imaging resources are limited.
methodsA total of 2187 cases were collected for the prediction model. Another 2026 cases from a new data set were utilized for performing independent temporal validation. The LASSO regression analysis was used to control possible variables. A final screening or triage nomogram for HFpEF was established based on logistic regression, and the discrimination and calibration of the established nomogram were evaluated by bootstrapping with 1000 resamples.
resultsThe final nomogram for screening or triage prevalent HFpEF was constructed using nine predictors retained in the final model: Age, systolic blood pressure (SBP), monocyte ratio (MONO%), red cell distribution width-coefficient of variation (RDW-CV), fasting glucose (GLU), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), Urea, and immunoglobulin G (IgG). The model demonstrated good discrimination, with a C-index of 0.762 in the training cohort and 0.783 in the validation cohort. Calibration plots showed good agreement between predicted and observed probabilities in both cohorts. Internal and temporal validation indicated that the model was robust and reliable.
conclusionsThis cross-sectional screening prediction nomogram estimates individualized risk of prevalent HFpEF using readily non-imaging variables and may support screening or triage and efficient allocation of echocardiography resources across hospital and community workflows. The tool is intended to prioritize referral for echocardiographic confirmation rather than replace guideline-based diagnosis. Prospective multicenter studies are warranted to evaluate transportability, clinical utility, and implementation impact.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.